TELETRADER News
7/5, 1:57 PM (Source: TeleTrader)
more TeleTrader news

CureVac sues BioNTech over vaccine technology

CureVac N.V. announced on Tuesday it filed a lawsuit against BioNTech SE, accusing the company of infringement of its intellectual property rights regarding mRNA vaccine technology, in which CureVac claims to have been "the earliest pioneer."

The biopharmaceutical company claimed BioNTech used the technology CureVac had been developing for over 20 years to make its COVID-19 vaccine in cooperation with Pfizer. "The CureVac intellectual property portfolio protects multiple inventions that are considered essential to the design and development of BioNTech’s SARS CoV-2 mRNA vaccine, among others. These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression, as well as mRNA vaccine formulations specific to SARS CoV-2 vaccines," CureVac said in a press release.

However, CureVac insisted it does not intend to seek "an injunction nor intend to take legal action that impedes the production, sale or distribution" of the Pfizer/BioNTech jab, noting it just wants its intellectual property rights "to be acknowledged and respected in the form of a fair compensation to reinvest into the further advancement of mRNA technology and the ongoing development of new classes of life-saving medicines."

Baha Breaking News (BBN) / NP